Navigation Links
Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Date:3/2/2011

NEW YORK and OSAKA, Japan, March 2, 2011 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.

Under the terms of the agreement, ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda. Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

"Takeda's strength in CNS drug development and commercialization complements ITI's innovative approach to discovery, research and development," said Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc. "We are delighted to be working together with Takeda to advance the development of our novel PDE1 inhibitors. This program represents a unique approach to the treatment of cognitive impairment associated with schizophrenia (CIAS) and other disorders."

"We are able to enhance our central nervous system pipeline, one of our Core Therapeutic Areas, through this collaboration," said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda Pharmaceutical Company Limited. "We believe that ITI's PDE1 inhib
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
2. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
5. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
6. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
7. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
8. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
9. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
10. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
11. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Decision ... (EP) mapping and ablation device market will ... ablation to treat atrial fibrillation (AF). The ... treatment option for AF will spur adoption ... application, such as advanced loop diagnostic catheters, ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
(Date:8/21/2014)... August 21, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Dianeal ... US FDA announced on August 15, that two lots ... 2.5% Dextrose 5000mL (Ambu-Flex II), by Baxter International Inc., ... particulate matter. , The reason for the recall ...
(Date:8/21/2014)... TX (PRWEB) August 21, 2014 Sometimes you have ... , In his new book “From Zero to a Hundred: Finding ... officer, shares his story of surviving a broken family, a childhood ... brings affirmation of who you were created to be,” Roy said. ... which is why I know my purpose today of helping others ...
(Date:8/21/2014)... 2014 OpsAssure, the local start-up ... to participate in the Harbor Accelerator's 14 week ... sessions and valuable resources.he Harbor’s goal is to ... Each start-up selected for the program receives a ... help businesses grow quickly, test markets and become ...
(Date:8/21/2014)... Today, Fecbek.com, a leading wedding dresses ... of wedding dresses. And all these elegant, gorgeous and ... excellent designers. , A wedding dress or wedding gown ... wedding ceremony. Color, style and ceremonial importance of the ... the wedding participants. In order to satisfy every customer, ...
(Date:8/20/2014)... Fancyflyingfox.com, the popular online supplier of wedding ... a new collection of 2014 military ball gowns ... promotion for these trendy and elegant products. , ... special offer to show its appreciation to the global ... ball outfits are provided with deeply discounted prices, up ...
Breaking Medicine News(10 mins):Health News:Dianeal Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Elegant Wedding Dresses Are for Sale at Fecbek.com 2Health News:2014 Military Ball Gowns Offered At Popular Online Store Fancyflyingfox.com 2
... VIRGINIA BEACH, Va., June 10 AMERIGROUP,Corporation (NYSE: ... full-year,2008 guidance of $2.35 to $2.45 per diluted share ... of Tennessee. As previously,announced, the Company will present at ... In the first quarter of 2008, AMERIGROUP disclosed higher ...
... of Christopher,Grell have filed a lawsuit against Herbalife Ltd. ... State of California (case BC392373, dept. 48) today,on behalf ... after,taking Herbalife products., The lawsuit, which also names ... Phillis Chen, a resident,of the State of California, suffered ...
... June 10 Mylan Inc. (NYSE: MYL ),announced ... Federal Circuit has,affirmed a May 2007 District Court ruling ... capsules do not infringe patents asserted,against Mylan by AstraZeneca. ... Mylan launched its Omeprazole products on August 4, 2003, ...
... June 10 More and more people today ... difficult to get and,stay healthy. This National Men,s ... that are helping people who are uninsured but,need ... this report from Pfizer (NYSE: PFE ) ...
... items keep addiction affordable, study says , , ... the United States have declined in recent years, but ... the decline in cigarette sales by 30 percent, a ... analyzed federal government data and found that between 2000 ...
... helped with depression, agitation in elderly , , TUESDAY, June ... may ease some of the behavioral problems associated with ... a hormone which seems to play a role in ... night. , Both strategies could greatly improve quality of ...
Cached Medicine News:Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 2Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 3Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 4Health News:AMERIGROUP Provides Status on Tennessee Rate Increase and Effect on 2008 Guidance 5Health News:Herbalife Sued for Negligence and Fraud by Victim 2Health News:Decline in Cigarette Sales Offset by Use of Alternative Products 2Health News:Adding Light Eases Behavioral Problems of Dementia 2Health News:Adding Light Eases Behavioral Problems of Dementia 3
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. The ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
... InstaCheck® multi-drug test device provides ... easily. Negative results can be ... 3 minutes; positive results require ... one-time urine sample application will ...
... Drug Screen Tests are available in 14 ... (Ecstasy). Designed using Microgenics Antibody Technology, the ... point of care immunoassay targeted to detect ... MDA and MDEA but no cross-reactivity to ...
Medicine Products: